Navigation Links
Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
Date:3/6/2008

Majority of DVT Cases Treated in Single-Setting With Trellis-8 Catheter

From Bacchus Vascular, Reducing Patient Lytic Exposure, Bleeding

Complications and Treatment Cost

SANTA CLARA, Calif., March 6 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and interventional cardiologists for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that the Journal of Vascular Interventional Radiology (JVIR) has published a study comparing the clinical use of the Trellis-8 infusion catheter from Bacchus Vascular with conventional catheter-directed thrombolysis (CDT) in the treatment of DVT in its March 2008 issue.

Results of the study showed that Grade II and III lysis was achieved in 93% of patients treated with the Trellis catheter and 79% of patients treated with CDT even though thrombolytic doses and infusion durations were less with the Trellis catheter than with conventional CDT. Major hemorrhage was reported in none of the Trellis catheter patients and in 8.5% of patients treated with CDT. The per-patient cost of therapy was $3,697 for the Trellis catheter and $5,473 for CDT. This cost reduction is due to approximately 80% of the Trellis catheter patients being treated in the single-setting of the interventional suite with less time required for follow-up monitoring in a costly critical care unit compared with CDT patients.

The study, which was authored by Daniel E. Hilleman, PharmD (Department of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE) and Mahmood K. Razavi, MD (Department of Vascular and Interventional Radiology, Stanford University Hospital, Stanford, CA), compared retrospectively collected data from 147 patients treated for DVT with the Trellis-8 infusion catheter at 45 hospitals in the U.S. and three hospitals outside the U.S. with a meta-analysis of 14 published studies in the medical literature in which CDT was performed on a minimum of 15 patients with DVT.

"We are gratified to see this rigorously-analyzed comparative data published in a major medical journal," stated Scott Cramer, President and CEO of Bacchus Vascular. "We continue to believe in both the strong clinical and economic utility of the Trellis infusion catheter as recognition increases in the medical community of the benefit of early DVT intervention in combating post-thrombotic syndrome and potential future DVT events."

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.


'/>"/>
SOURCE Bacchus Vascular Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
2. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
3. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
6. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
7. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
8. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
9. AMTs Lead Product Poised to Address Major Liver Disease
10. SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
11. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):